Ergomed PLC (AIM:ERGO, ETR:2EM, FRA:2EM)'s (LON:ERG) Richard Barfield delivers the company's trading update for the first half of 2021.
Among the highlights include total revenues for the period of £56.0 million, up from £40.4 million for the same period last year, an increase of 38.8%.
As well as delivering strong results and operational progress during the first half of the year, the firm has concluded their transition to a services-based business model and rapidly integrated recent acquisitions as Barfield explains.
Growth in the pharmacovigilance business has continued and the CRO business saw a substantial revenue increase supported by the recent US acquisition.